BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waetzig R, Matthes M, Leister J, Penkivech G, Heise T, Corbacioglu S, Sommer G. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells. Int J Med Sci 2021;18:137-49. [PMID: 33390782 DOI: 10.7150/ijms.48393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Braoudaki M, Hatziagapiou K, Zaravinos A, Lambrou GI. MYCN in Neuroblastoma: "Old Wine into New Wineskins". Diseases 2021;9:78. [PMID: 34842635 DOI: 10.3390/diseases9040078] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
2 Brenner AK, Gunnes MW. Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update. Pharmaceutics 2021;13:1427. [PMID: 34575503 DOI: 10.3390/pharmaceutics13091427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 2021:S1044-579X(21)00188-7. [PMID: 34175443 DOI: 10.1016/j.semcancer.2021.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bhoopathi P, Mannangatti P, Emdad L, Das SK, Fisher PB. The quest to develop an effective therapy for neuroblastoma. J Cell Physiol 2021. [PMID: 33834508 DOI: 10.1002/jcp.30384] [Cited by in F6Publishing: 4] [Reference Citation Analysis]